BioStem TechnologiesBSEM +1.74%49 Quick Ratio is 4.09 as of Sep. 2025, which is 3990% above its 10-year median of 0.10. GuruFocus rates BSEM with a GF Score™ of 49/100 and a GF Value™ of $139.96 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, BioStem Technologies ranks better than 53.32% on this metric.
BioStem Technologies has a quick ratio of 4.09. It generally indicates good short-term financial strength.
The historical rank and industry rank for BioStem Technologies's Quick Ratio or its related term are showing as below:
BSEM'
s Quick Ratio Range Over the Past 10 Years
Min: 0.02 Med: 0.1 Max: 4.09
Current: 4.09
During the past 13 years, BioStem Technologies's highest Quick Ratio was 4.09. The lowest was 0.02. And the median was 0.10.
BSEM's Quick Ratio is ranked better than 53.32% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs BSEM: 4.09
BioStem Technologies (OTCPK:BSEM) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
BioStem Technologies Quick Ratio Related Terms
BioStem Technologies Quick Ratio Historical Data
* Premium members only.
The historical data trend for BioStem Technologies's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioStem Technologies's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioStem Technologies Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioStem Technologies's Quick Ratio distribution charts can be found below:
* The bar in red indicates where BioStem Technologies's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
BioStem Technologies's Quick Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioStem Technologies (BSEM) has a Quick Ratio of 4.09 as of Sep. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on BioStem Technologies and its competitors. This is 3990% above median its historical median of 0.10. Over the past decade, BioStem Technologies' Quick Ratio has ranged from 0.02 to 4.09. According to the industry distribution chart, BioStem Technologies ranks #661 out of 1416 companies in the Biotechnology industry, placing it in the top 46.7%.
Is BioStem Technologies' Quick Ratio too high?
BioStem Technologies' current Quick Ratio of 4.09 is 3990% above median its 10-year median of 0.10. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 4.09. The Biotechnology industry median Quick Ratio is 3.60. BioStem Technologies' value of 4.09 is 13.6% above this industry median. Based on the distribution chart, BioStem Technologies ranks #661 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioStem Technologies has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' Quick Ratio compare to TCRX and BYSI?
According to the Biotechnology industry distribution chart, BioStem Technologies ranks #661 out of 1416 companies for Quick Ratio. This puts BioStem Technologies in the upper half of its industry. The industry median Quick Ratio is 3.60. BioStem Technologies' value of 4.09 is 13.6% above this benchmark. Historically, BioStem Technologies' own Quick Ratio has ranged from 0.02 to 4.09 over the past decade. While the company's 10-year median is 0.10 vs. the industry median of 3.60, BioStem Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioStem Technologies's current Quick Ratio of 4.09 is 13.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on BioStem Technologies and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioStem Technologies's current Quick Ratio is 4.09, which is 3990% above median its own 10-year median of 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
Based on GuruFocus' analysis, BioStem Technologies (BSEM) is currently considered Possible Value Trap. The stock's GF Value™ is $139.96, compared to a current price of $3.50 — trading 97.5% below its estimated fair value. The current Quick Ratio is 4.09, which is 3990% above median its 10-year median of 0.10 and 13.6% above the Biotechnology industry median of 3.60. BioStem Technologies' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current Quick Ratio is 4.09 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioStem Technologies (BSEM) Overvalued in 2026?
Based on GuruFocus' analysis, BioStem Technologies stock appears to be undervalued.
The current stock price of $3.50 is trading 97.5% below its estimated GF Value™ of $139.96.
GuruFocus considers BioStem Technologies to be Possible Value Trap.
Key valuation signals for BSEM:
Quick Ratio: 4.09 (3990% above median its 10-year median of 0.10)
GF Value™: $139.96 vs. price of $3.50 (97.5% below fair value)
Industry Position: 13.6% above the Biotechnology median (#661 of 1416)
No single metric tells the full story. See the BSEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
49GF Score
Get the complete analysis for BSEM
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSEM has been successfully added to your 
